Mobile

An open-label, multicenter phase II extension of study 28063 (ATAMS) to obtain long-term follow-up data in patients with relapsing multiple sclerosis treated with atacicept for up to 5 years (ATAMS-Ex...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-005021-11

An open-label, multicenter phase II extension of study 28063 (ATAMS) to obtain long-term follow-up data in patients with relapsing multiple sclerosis treated with atacicept for up to 5 years (ATAMS-Extension)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The main objective of the study is to monitor the long-term safety and tolerability of atacicept administered for up to 5 years to subjects with relapsing multiple sclerosis (RMS).

Critère d'inclusion

  • Relapsing Multiple Sclerosis

Liens